Share on StockTwits
 

Shares of InterMune (NASDAQ:ITMN) were the recipient of some unusual options trading on Tuesday. Traders purchased 14,228 put options on the stock, Stock Ratings Network reports. This represents an increase of approximately 729% compared to the average volume of 1,716 put options.

A number of research firms have recently commented on ITMN. Analysts at Leerink Swann downgraded shares of InterMune to a “market perform” rating in a research note on Wednesday. Separately, analysts at Jefferies Group raised their price target on shares of InterMune from $7.00 to $20.00 in a research note on Wednesday. Finally, analysts at Credit Suisse raised their price target on shares of InterMune from $15.00 to $33.00 in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $26.45.

InterMune (NASDAQ:ITMN) opened at 37.80 on Wednesday. InterMune has a 1-year low of $8.41 and a 1-year high of $38.73. The stock’s 50-day moving average is $15.75 and its 200-day moving average is $14.57. The company’s market cap is $3.101 billion.

InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.